To provide a combination of drugs to treat multiple myeloma. The present invention relates to the combination of c-met inhibitors and proteasome inhibitors for the treatment of multiple myeloma.The overall survival and remission duration of patients with multiple myeloma (mm) significantly improve the...
A stem cell transplant is a common treatment for multiple myeloma. If you’re able to have one, you’ll get induction therapy followed by a high dose of a chemotherapy drug to kill as many cancer cells as possible. Or your doctor might give you a combination of some of the other medici...
“Selinexor offers an additional treatment option for patients with multiple myeloma, allowing more personalised treatment. “Pembrolizumab will provide a treatment for people who have had surgery to remove lung cancer but are at a high risk of the cancer coming back.”...
This review will focus on the preclinical and clinical activity of thalidomide and its more potent immunomodulatory derivatives that are used to treat . They represent a new class of antitumor agents that not only target the cell directly, but also have significant activity within the bone marrow ...
Tecvayli, from Janssen Pharmaceuticals, is used to treat multiple myeloma (bone marrow cancer) in adults who have not responded to at least 4 prior treatments (including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody), or who have relapsed despite prior ...
Reported single-agent activity of new drugs in relapsed refractory multiple myeloma Agent Patient characteristics No. of patientsa PRR ORR (%) (partial +minor) Isatuximab20 Median five prior lines of therapy (range 2–10). 88% Dual refractoryb Marizomib24 Median five to seven prior lines of...
Velcade (bortezomib) is used to treat multiple myeloma (MM) and mantle cell lymphoma (MCL) in adults. Velcade injection is a proteasome inhibitor, a type of targeted cancer drug. Velcade injection is not chemotherapy. Velcade works by blocking enzymes (proteasomes), which usually break down ...
Multiple Myeloma Drug Pipeline Venetoclax Venetoclax (Venclexta; AbbVie) is an oral BCL2 inhibitor drug currently FDA approved to treat chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and acute myeloid leukemia. Additionally, venetoclax is being studied for the treatment ...
A north-south divide threatens to emerge in multiple myeloma in the UK, after the Scottish Medicines Consortium (SMC) backed NHS use of two drugs previously turned down by NICE in England. The SMC has accepted use by NHS Scotland of Bristol-Myers Squibb’s Revlimid (lenalidomide) and Amgen...
(Prozac) and is now undergoing Phase III clinical trials as a first-in-class therapy for premature ejaculation; and thalidomide, which had a tragic beginning as an over-the-counter sedative for morning sickness in Germany and England and is now being used to treat leprosy and multiple myeloma...